Back to today’s briefing

Story perspectives

FDA Approves Vykat XR: Hope for Prader-Willi Patients

3/26/2025

50 12

Summary

Story summary

The U.S. FDA has granted approval for Soleno Therapeutics' Vykat XR, a groundbreaking treatment for Prader-Willi syndrome, a rare genetic disorder characterized by insatiable hunger. Set to launch in April 2025 for those aged four and up, this milestone brings hope to the 50,000 individuals affected by this condition, marking a new chapter in their journey.

1 of 1

Story summary

The U.S. FDA has granted approval for Soleno Therapeutics' Vykat XR, a groundbreaking treatment for Prader-Willi syndrome, a rare genetic disorder characterized by insatiable hunger. Set to launch in April 2025 for those aged four and up, this milestone brings hope to the 50,000 individuals affected by this condition, marking a new chapter in their journey.